Published in PLoS One on January 20, 2017
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science (1999) 4.78
Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol (1996) 4.45
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Antibiotic resistance: the last resort. Nature (2013) 2.20
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med (2014) 1.76
Klebsiella pneumoniae lipopolysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J Clin Microbiol (1999) 1.75
wzi Gene sequencing, a rapid method for determination of capsular type for Klebsiella strains. J Clin Microbiol (2013) 1.46
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
Klebsiella: a long way to go towards understanding this enigmatic jet-setter. F1000Prime Rep (2014) 1.43
Type 3 fimbrial shaft (MrkA) of Klebsiella pneumoniae, but not the fimbrial adhesin (MrkD), facilitates biofilm formation. Infect Immun (2001) 1.37
Klebsiella pneumoniae MrkD-mediated biofilm formation on extracellular matrix- and collagen-coated surfaces. Microbiology (2003) 1.35
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A (2013) 1.23
Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis (1996) 1.21
Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med (2012) 1.15
Klebsiella pneumoniae and type 3 fimbriae: nosocomial infection, regulation and biofilm formation. Future Microbiol (2012) 1.05
Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine (1994) 1.00
Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun (2015) 0.90
Target-Agnostic Identification of Functional Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit. J Infect Dis (2016) 0.89
Anti-endotoxin vaccines: back to the future. Virulence (2013) 0.86
Development of phage-based single chain Fv antibody reagents for detection of Yersinia pestis. PLoS One (2011) 0.85
Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine (2008) 0.83
A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format. PLoS One (2015) 0.83
Identification of protein domains on major pilin MrkA that affects the mechanical properties of Klebsiella pneumoniae type 3 fimbriae. Langmuir (2012) 0.80
Development of a homogeneous high-throughput screening assay for biological inhibitors of human rhinovirus infection. J Biomol Screen (2012) 0.78
A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells. MAbs (2016) 0.77
Immunotherapies against antibiotics-resistant Klebsiella pneumoniae. Hum Vaccin Immunother (2016) 0.77